$DARE
Dare Bioscience, Inc.

2023 Q1 Form 10-K Financial Statement

#000140191423000013 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $10.00M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.362M $3.254M $11.34M
YoY Change 29.57% 34.09% 34.22%
% of Gross Profit
Research & Development $5.020M $12.98M $30.04M
YoY Change -13.53% 82.35% -1.88%
% of Gross Profit
Depreciation & Amortization $9.508K $10.62K $24.20K
YoY Change 81.9% 50.85% -8.37%
% of Gross Profit
Operating Expenses $8.383M $16.23M $41.39M
YoY Change -0.21% 70.08% 5.93%
Operating Profit -$8.383M -$31.39M
YoY Change -0.21% -19.67%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $340.1K $287.3K $437.8K
YoY Change 19020.18% 34519.28% 17271.03%
Pretax Income -$8.043M -$15.94M -$30.95M
YoY Change -4.24% 67.08% -20.02%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.000M -$15.94M -$30.90M
YoY Change -4.76% 67.08% -20.16%
Net Earnings / Revenue -309.0%
Basic Earnings Per Share -$0.09 -$0.37
Diluted Earnings Per Share -$0.09 -$0.20 -$0.37
COMMON SHARES
Basic Shares Outstanding 86.18M shares 84.83M shares 84.57M shares
Diluted Shares Outstanding 85.52M shares 84.57M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.83M $34.67M $34.67M
YoY Change -49.57% -32.91% -32.91%
Cash & Equivalents $19.83M $34.67M $34.67M
Short-Term Investments
Other Short-Term Assets $201.4K $6.666M $6.666M
YoY Change -97.03% 169.16% 169.16%
Inventory
Prepaid Expenses $7.082M $6.666M
Receivables
Other Receivables $2.399M $1.703M
Total Short-Term Assets $29.51M $43.04M $43.04M
YoY Change -38.28% -22.17% -22.17%
LONG-TERM ASSETS
Property, Plant & Equipment $55.40K $64.91K $522.8K
YoY Change 118.4% 149.25% 115.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $799.3K $722.7K $264.8K
YoY Change -40.53% 48.98% -1.36%
Total Long-Term Assets $854.7K $787.6K $787.6K
YoY Change -37.58% 54.09% 54.09%
TOTAL ASSETS
Total Short-Term Assets $29.51M $43.04M $43.04M
Total Long-Term Assets $854.7K $787.6K $787.6K
Total Assets $30.37M $43.83M $43.83M
YoY Change -38.26% -21.47% -21.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.696M $2.028M $2.028M
YoY Change -4.78% -3.57% -3.57%
Accrued Expenses $5.480M $10.89M $11.29M
YoY Change 54.9% 247.36% 231.47%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.34M $31.62M $31.62M
YoY Change 48.45% 97.0% 97.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.057M $1.090M $1.090M
YoY Change -44.74% 9.04%
Total Long-Term Liabilities $1.057M $1.090M $1.090M
YoY Change -44.74% 9.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.34M $31.62M $31.62M
Total Long-Term Liabilities $1.057M $1.090M $1.090M
Total Liabilities $25.40M $32.71M $32.71M
YoY Change 38.71% 91.84% 91.84%
SHAREHOLDERS EQUITY
Retained Earnings -$149.1M -$141.1M
YoY Change 25.82% 28.12%
Common Stock $154.5M $152.5M
YoY Change 3.27% 2.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.972M $11.11M $11.11M
YoY Change
Total Liabilities & Shareholders Equity $30.37M $43.83M $43.83M
YoY Change -38.26% -21.47% -21.47%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$8.000M -$15.94M -$30.90M
YoY Change -4.76% 67.08% -20.16%
Depreciation, Depletion And Amortization $9.508K $10.62K $24.20K
YoY Change 81.9% 50.85% -8.37%
Cash From Operating Activities -$16.12M -$5.897M -$18.09M
YoY Change 30.58% -40.53% -37.11%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.700K $63.07K
YoY Change -100.0% 334.24%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$2.700K -$63.07K
YoY Change -100.0% 334.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.300M
YoY Change -92.02%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.299M -10.00 $1.343M
YoY Change -100.0% -98.23%
NET CHANGE
Cash From Operating Activities -$16.12M -5.897M -$18.09M
Cash From Investing Activities $0.00 -2.700K -$63.07K
Cash From Financing Activities $1.299M -10.00 $1.343M
Net Change In Cash -$14.84M -5.899M -$17.00M
YoY Change 20.09% -196.9% -136.18%
FREE CASH FLOW
Cash From Operating Activities -$16.12M -$5.897M -$18.09M
Capital Expenditures $0.00 $2.700K $63.07K
Free Cash Flow -$16.12M -$5.899M -$18.15M
YoY Change 30.53% -40.51% -36.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001401914
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
102284000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86178996 shares
CY2022 dei Auditor Firm
AuditorFirmId
199
CY2022 dei Auditor Name
AuditorName
Mayer Hoffman McCann P.C.
CY2022 dei Auditor Location
AuditorLocation
San Diego, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34669605 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51674087 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1703160 usd
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1145317 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6665988 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2476612 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
43038753 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
55296016 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64908 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26041 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
722722 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
485120 usd
CY2022Q4 us-gaap Assets
Assets
43826383 usd
CY2021Q4 us-gaap Assets
Assets
55807177 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2027953 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2103083 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10894016 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3136244 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90346 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Liabilities
Liabilities
32714273 usd
CY2021Q4 us-gaap Liabilities
Liabilities
17052856 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83944119 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83944119 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8482 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8394 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-351311 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-154973 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
152529579 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
149027802 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141074640 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110126902 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11112110 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38754321 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43826383 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55807177 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30042217 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30617567 usd
CY2022 dare License Fee Expense
LicenseFeeExpense
100000 usd
CY2021 dare License Fee Expense
LicenseFeeExpense
100000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
41385488 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
39068512 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-31385488 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-39068512 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
437750 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2520 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-30947738 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-38696105 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30947738 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38696105 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84571805 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84571805 shares
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75314091 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
500146 usd
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32529 usd
CY2021 dare Stock Issued During Period Value Milestone Payment
StockIssuedDuringPeriodValueMilestonePayment
1219286 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-38696105 usd
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-63585 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38754321 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2158511 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1218750 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
124604 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-196338 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11112110 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-30947738 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-38696105 usd
CY2022 us-gaap Depreciation
Depreciation
24202 usd
CY2021 us-gaap Depreciation
Depreciation
26413 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2158511 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1599692 usd
CY2022 dare Non Cash Lease Expense
NonCashLeaseExpense
23415 usd
CY2021 dare Non Cash Lease Expense
NonCashLeaseExpense
-96132 usd
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
46477 usd
CY2021 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0 usd
CY2022 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
44286 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 usd
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
557842 usd
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
685149 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4189376 usd
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
622336 usd
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3650 usd
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-20873 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-75132 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1081749 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7757774 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-45871 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
124604 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32529 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1343354 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75846766 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-196338 usd
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-63585 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17004482 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
47004620 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51674087 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4669467 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
585942 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
308533 usd
CY2022 dare Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability
NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
0 usd
CY2021 dare Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability
NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
925000 usd
CY2022 dare Milestone Payments Contingent Amount
MilestonePaymentsContingentAmount
0 usd
CY2021 dare Milestone Payments Contingent Amount
MilestonePaymentsContingentAmount
250000 usd
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141100000 usd
CY2022Q4 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
18300000 usd
CY2022Q4 dare Working Capital Increase Deficit
WorkingCapitalIncreaseDeficit
11400000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18100000 usd
CY2022 dare Periodof Insufficient Cashand Liquidity Requirements
PeriodofInsufficientCashandLiquidityRequirements
P12M
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 dare Grant Funding Recognized During Period
GrantFundingRecognizedDuringPeriod
5600000 usd
CY2021Q4 dare Grant Funding Recognized During Period
GrantFundingRecognizedDuringPeriod
2500000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.</span></div>
CY2022Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
35000 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash balances at various financial institutions and such balances commonly exceed the $250,000 amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in the U.S. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant risk with respect to such cash and cash equivalents.</span></div>
CY2021Q3 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
700000 shares
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2300000 usd
CY2022 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company has entered into indemnification agreements with its officers and directors that provide that the Company will indemnify its directors and officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by such director or officer in any action or proceeding arising out of their service as a director and/or officer. The term of the indemnification is for the officer’s or director’s lifetime. During the year ended December 31, 2022, the Company did not experience any losses related to those indemnification obligations. The Company does not expect significant claims related to these indemnification obligations, and consequently, has concluded the fair value of the obligations is not material. Accordingly, as of December 31, 2022 and 2021, no amounts have been accrued related to such indemnification provisions.</span></div>
CY2021Q4 dare Accrued Indemnification Provisions
AccruedIndemnificationProvisions
0 usd
CY2022Q4 dare Accrued Indemnification Provisions
AccruedIndemnificationProvisions
0 usd
CY2022Q4 dare Prepaid Clinical Expense
PrepaidClinicalExpense
5928090 usd
CY2021Q4 dare Prepaid Clinical Expense
PrepaidClinicalExpense
1728421 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
502981 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
552354 usd
CY2022Q4 dare Prepaid Professional Expense
PrepaidProfessionalExpense
234917 usd
CY2021Q4 dare Prepaid Professional Expense
PrepaidProfessionalExpense
195837 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6665988 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2476612 usd
CY2022Q4 dare Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
0 usd
CY2021Q4 dare Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
87891 usd
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
115092 usd
CY2021Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
0 usd
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
139203 usd
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
143002 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10502 usd
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
37554 usd
CY2022Q4 dare Operating Lease Right Of Use Asset Noncurrent
OperatingLeaseRightOfUseAssetNoncurrent
457925 usd
CY2021Q4 dare Operating Lease Right Of Use Asset Noncurrent
OperatingLeaseRightOfUseAssetNoncurrent
216673 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
722722 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
485120 usd
CY2022Q4 dare Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
6665443 usd
CY2021Q4 dare Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
1242414 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1720501 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1533475 usd
CY2022Q4 dare Accrued Development Expense Current
AccruedDevelopmentExpenseCurrent
2102310 usd
CY2021Q4 dare Accrued Development Expense Current
AccruedDevelopmentExpenseCurrent
158103 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
239348 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
129858 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99747 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5727 usd
CY2022Q4 dare Accrued License Expense Current
AccruedLicenseExpenseCurrent
66667 usd
CY2021Q4 dare Accrued License Expense Current
AccruedLicenseExpenseCurrent
66667 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10894016 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3136244 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28391000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37083000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2557000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1613000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30948000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38696000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0296
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0964
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.0908
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2022 dare Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0002
CY2021 dare Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0019
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0684
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0270
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0057
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0041
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.0074
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.1448
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3338
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0001
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0001
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
81761000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
81817000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8833000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7186000 usd
CY2022Q4 dare Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
10009000 usd
CY2021Q4 dare Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
7417000 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1468000 usd
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
801000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2170000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2540000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
104241000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
99761000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
104241000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
99761000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
104200000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
99800000 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4500000 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14500000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
900000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
117800000 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1909000 usd
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1341000 usd
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
427000 usd
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
426000 usd
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
20000 usd
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
142000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2316000 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1909000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2300000 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q4 dare Unremitted Earnings
UnremittedEarnings
0 usd
CY2021Q4 dare Percentage Of Aggregate Commission
PercentageOfAggregateCommission
0.03
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
50000000 usd
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
751000 shares
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1300000 usd
CY2022 dare Offering Expenses
OfferingExpenses
42000 usd
CY2021 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7100000 shares
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16300000 usd
CY2021 dare Offering Expenses
OfferingExpenses
537000 usd
CY2021Q2 dare Percentage Of Aggregate Commission
PercentageOfAggregateCommission
0.03
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
175000 usd
CY2022Q4 dare Deferred Offering Costs Unamortized Portion
DeferredOfferingCostsUnamortizedPortion
0 usd
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.00
CY2019Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.98
CY2020Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.96
CY2019Q2 dare Deemed Dividend From Trigger Of Round Down Provision Feature
DeemedDividendFromTriggerOfRoundDownProvisionFeature
800000 usd
CY2020Q3 dare Deemed Dividend From Trigger Of Round Down Provision Feature
DeemedDividendFromTriggerOfRoundDownProvisionFeature
6863 usd
CY2022 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0 shares
CY2021 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
520985 shares
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
500000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1381015 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84825481 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84825481 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83944119 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83944119 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17570150 shares
CY2022Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
4100000 usd
CY2022 dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P2Y4M24D
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2158511 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1599692 usd
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0200
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0067
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.21
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.30
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.01
CY2018Q3 us-gaap Net Rentable Area
NetRentableArea
3169 sqft
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2022Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-504000 usd
CY2022 dare Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-458000 usd
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
46000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
458000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
398000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
602000 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
561000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
346000 usd
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
462000 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M29D
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
422000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
93000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
515000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
26000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
489000 usd
CY2020Q2 dare Coronavirus Aid Reliefand Economic Security Act Loan Proceeds Received
CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived
367285 usd
CY2021Q1 dare Notes Payable Current Plus Accrued Interest
NotesPayableCurrentPlusAccruedInterest
369887 usd
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000 usd
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
160000 usd
dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
1900000 usd

Files In Submission

Name View Source Status
dare-20221231_cal.xml Edgar Link unprocessable
0001401914-23-000013-index-headers.html Edgar Link pending
0001401914-23-000013-index.html Edgar Link pending
0001401914-23-000013.txt Edgar Link pending
0001401914-23-000013-xbrl.zip Edgar Link pending
dare-20221231.htm Edgar Link pending
dare-20221231.xsd Edgar Link pending
dare-20221231xex106d.htm Edgar Link pending
dare-20221231xex211.htm Edgar Link pending
dare-20221231xex231.htm Edgar Link pending
dare-20221231xex311.htm Edgar Link pending
dare-20221231xex312.htm Edgar Link pending
dare-20221231xex321.htm Edgar Link pending
dare-20221231xex322.htm Edgar Link pending
dare-20221231_g1.jpg Edgar Link pending
dare-20221231_g2.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
dare-20221231_lab.xml Edgar Link unprocessable
dare-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dare-20221231_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dare-20221231_def.xml Edgar Link unprocessable